Clear Street analyst Bill Maughan upgraded Crispr Therapeutics (CRSP) to Buy from Hold with an unchanged price target of $45. The company reported Q1 results that were largely inline with expectations and the slow launch facing Casgevy is well understood, the analyst tells investors in a research note. The firm says expectations are “much more reasonable now than they had been previously.” It cites valuation for the upgrade.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Crispr Therapeutics AG: Balancing Growth Potential with Profitability Challenges – Hold Rating
- Crispr Therapeutics reports Q1 EPS ($1.58), consensus ($1.28)
- Cathie Wood Makes Surprising Moves by Buying AMD and Selling CRISPR
- ‘Incoming Regulatory Tailwinds’ to Spur 90% Upside for CRISPR Therapeutics Stock, Says BMO Capital
- Crispr Therapeutics AG: Promising Growth with Casgevy Launch and Innovative Pipeline